The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: Preliminary results.
Christophe Massard
Consultant or Advisory Role - Janssen Pharmaceutical ; Sanofi
Carmel Pezaro
Employment or Leadership Position - Institute of Cancer Research, ICR
Honoraria - Sanofi
Other Remuneration - Janssen Pharmaceutical
Dmitri Bobilev
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Aurelius Gabriel Omlin
Employment or Leadership Position - Institute of Cancer Research, ICR
Diletta Bianchini
No relevant relationships to disclose
David Lorente Estelles
Employment or Leadership Position - Institute of Cancer Research, ICR
Laurence Albiges
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Yohann Loriot
Honoraria - Sanofi
Research Funding - Sanofi
Andrea Varga
No relevant relationships to disclose
Thi Xuan Quyen Nguyen
Employment or Leadership Position - Sanofi
Karim Fizazi
Consultant or Advisory Role - Janssen Pharmaceutical ; Sanofi
Johann Sebastian De Bono
Employment or Leadership Position - Institute of Cancer Research, ICR
Consultant or Advisory Role - Sanofi
Honoraria - Astellas Pharma; Johnson & Johnson; Sanofi
Research Funding - Sanofi